Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HMGCR | P04035 | 1/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.34 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.34 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.34 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.33 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.31 |
| ▸ | CPT2 | P23786 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21070027 | 0.80 | TDP1 (0.53) | GAAMEN1KMT2ATDP1 | |
| SCHEMBL20189667 | 0.79 | KMT2A (0.36) | HMGCRCHRM1TBXA2RADRA1AMEN1 | |
| SCHEMBL22028162 | 0.79 | KMT2A (0.36) | HMGCRCHRM1TBXA2RADRA1AMEN1 | |
| SCHEMBL5795037 | 0.77 | ALDH1A1 (0.39) | HMGCRCHRM1TBXA2RADRA1AGAA | |
| SCHEMBL16438125 | 0.74 | HMGCR (0.64) | HMGCRCHRM1TBXA2RADRA1AFFAR1 | |
| SCHEMBL10974694 | 0.74 | HMGCR (0.64) | HMGCRCHRM1TBXA2RADRA1AFFAR1 | |
| Bicarbonate SCHEMBL5505471 | 0.74 | HMGCR (0.42) | HMGCRCHRM1TBXA2RADRA1AMEN1 | |
| SCHEMBL22854215 | 0.71 | TDP1 (0.40) | HMGCRCHRM1TBXA2RADRA1AMEN1 | |
| SCHEMBL9390107 | 0.71 | MAPT (0.38) | MEN1KMT2A | |
| SCHEMBL2350690 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230398223-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230398223-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | HMGCR 1374/4885CHRM1 4719/4885TBXA2R 3772/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.